BioDrugs

, Volume 23, Issue 2, pp 125–135 | Cite as

Golimumab

In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Adis Drug Profile

Abstract

▴ Golimumab is a human anti-tumor necrosis factor (TNF) monoclonal antibody that acts principally by targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone.

▴ Large, randomized, double-blind trials in patients with rheumatoid arthritis who were methotrexate-naïve (GO-BEFORE) or -experienced (GO-FORWARD) have shown that golimumab 50 or 100 mg every 4 weeks, in combination with methotrexate, was more effective than methotrexate alone for improving signs and symptoms of arthritis at weeks 14 and/or 24, according to American College of Rheumatology (ACR) criteria.

▴ In patients with active rheumatoid arthritis despite previous treatment with anti-TNF agents (GO-AFTER), golimumab 50 or 100 mg every 4 weeks was more effective than placebo for improving ACR responses at weeks 14 and 24; most patients in the study received concomitant methotrexate.

▴ In patients with psoriatic arthritis in the GO-REVEAL study, significantly more golimumab than placebo recipients achieved a ≥20% improvement in ACR criteria at week 14.

▴ Golimumab was also superior to placebo for improving the signs and symptoms of ankylosing spondylitis in the GO-RAISE study; significantly more golimumab than placebo recipients achieved a ≥20% improvement in the Assessment in Ankylosing Spondylitis (ASAS) criteria at week 14.

▴ In the five phase III trials in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, there was no clear evidence of improved ACR or ASAS responses with the 100 mg dosage compared with the 50 mg dosage of golimumab.

▴ The tolerability profile of golimumab was generally consistent with that of other anti-TNF agents.

Keywords

Rheumatoid Arthritis Methotrexate Ankylose Spondylitis Spondylitis Psoriatic Arthritis 

Notes

Acknowledgments and Disclosures

The manuscript was reviewed by: S.J. Bowman, Rheumatology Department, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; P. Emery, Academic Unit of Musculoskeletal Disease, Leeds University, Leeds, United Kingdom; M.T. Nurmohamed, Departments of Internal Medicine and Rheumatology, VU University Medical Centre, Amsterdam, the Netherlands.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

References

  1. 1.
    Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008 Feb; 117(2): 244–79PubMedCrossRefGoogle Scholar
  2. 2.
    Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008 Jan; 58(1): 15–25PubMedCrossRefGoogle Scholar
  3. 3.
    Spondylitis Association of America. About spondylitis [online]. Available from URL: http://www.spondylitis.org/about/main.aspx?YYZ=NAV02 [Accessed 2009 Feb 19]
  4. 4.
    Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64Suppl. II: ii14–7PubMedCrossRefGoogle Scholar
  5. 5.
    Hutas G. Golimumab, a fully human monoclonal antibody against TNFa. Curr Opin Mol Ther 2008 Aug; 10(4): 393–406PubMedGoogle Scholar
  6. 6.
    Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008 Apr; 58(4): 964–75PubMedCrossRefGoogle Scholar
  7. 7.
    Visvanathan S, Gladman D, Brodmerkel C, et al. Identification of serum markers associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab [abstract no. SAT0315]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  8. 8.
    Visvanathan S, Inman RD, Braun J, et al. Identification of serum markers associated with improvement in clinical response measures in AS patients treated with golimumab [abstract no. SAT0276]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  9. 9.
    Visvanathan S, Rojas J, Wagner C, et al. Decreases in E-selectin, IL-18, SAA, and MMP-9 may predict clinical response to golimumab plus MTX therapy in rheumatoid arthritis patients [abstract no. FRI0197]. 2007 Annual European Congress of Rheumatology; 2007 Jun 13–16; BarcelonaGoogle Scholar
  10. 10.
    Shealy D, Cai A, Lacy E, et al. Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for human TNFalpha [abstract no. THU0088]. 2007 Annual European Congress of Rheumatology; 2007 Jun 13–16; BarcelonaGoogle Scholar
  11. 11.
    Simponi (golimumab) [US prescribing information]. Horsham (PA): Centocor Ortho Biotech Inc [online]. Available from URL: http://www.simponi.com/simponi/Prescribing-Information/Prescribing-Information.pdf [Accessed 2009 Apr 28]
  12. 12.
    Xu Z, Lee H, Vu T, et al. Population pharmacokinetics of golimumab, an antitumor necrosis factor-alpha human monoclonal antibody, in patients with rheumatoid arthritis [abstract no. FRI0149]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  13. 13.
    Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody in patients with psoriatic arthritis [abstract no. SAT0316]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  14. 14.
    Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody in patients with ankylosing spondylitis [abstract no. AB0675]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  15. 15.
    Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007 Mar; 47(3): 383–96PubMedCrossRefGoogle Scholar
  16. 16.
    Emery P, Fleischmann RM, Moreland LW, et al. Golimumab (GLM), a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously (SC) every 4 weeks in methotrexate-naive patients with active rheumatoid arthritis (RA): a randomized, double-blind, placebo-controlled, GO-BEFORE study [abstract no. THU0138]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  17. 17.
    Centocor, Inc. A study of the safety and efficacy of golimumab in subjects with rheumatoid arthritis that are methotrexate-naive [ClinicalTrials.gov identifier NCT00264537]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Feb 17]
  18. 18.
    Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to TNF-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GO-FORWARD study. Ann Rheum Dis Epub 2008 Dec 9Google Scholar
  19. 19.
    Smolen J, Kay J, Doyle MK, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo-C [abstract no. OP-0010]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  20. 20.
    US National Institutes of Health. A study of the safety and efficacy of golimumab (CNTO 148) in subjects with active rheumatoid arthritis previously treated with biologic anti-TNFalpha agents [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Feb 17]
  21. 21.
    Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor a antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Arthritis Rheum 2009 Apr; 60(4): 976–86PubMedCrossRefGoogle Scholar
  22. 22.
    Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new, human, TNF alpha antibody administered subcutaneously every 4 weeks in psoriatic arthritis patients: 52-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study [abstract no. OP-0161]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  23. 23.
    Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new, human, TNF-alpha antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL Study [abstract no. L14]. 71st Annual Scientific Meeting of the American College of Rheumatology and the 42nd Annual Meeting of the Association of Rheumatology Health Professionals: Late Breaker Abstracts; 2007 Nov 6–11; Boston (MA), 81-2Google Scholar
  24. 24.
    Inman RD, Davis Jr JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008 Nov; 58(11): 3402–12PubMedCrossRefGoogle Scholar
  25. 25.
    Buchanan J, Hsu B, Gathany T, et al. Improving functionality improves sleep in patients with active ankylosing spondylitis: results from the GO-RAISE study [abstract no. AB1016]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  26. 26.
    Braun J, Inman R, van der Heijde D, et al. Golimumab significantly improves productivity in patients with active ankylosing spondylitis: results from the phase 3 GO-RAISE study [abstract no. FRI0306]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  27. 27.
    van der Heijde D, Braun J, Davis Jr JC, et al. Head-to-head comparison of 3 enthesitis indices in the ankylosing spondylitis anti-TNF-alpha trial of golimumab (GO-RAISE) [abstract no. SAT0272]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  28. 28.
    Parasuraman S, Hsu B, Gathany T, et al. Is there a relationship between functionality and productivity in patients with active ankylosing spondylitis? Results from the GO-RAISE study [abstract no. SAT0454]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  29. 29.
    McInnes I, Kavanaugh A, Krueger GG, et al. Golimumab, a new human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: response to pneumococcal vaccine in the randomized, placebo-controlled, GO-REVEAL study [abstract no. SAT0302]. 2008 Annual European Congress of Rheumatology; 2008 Jun 11–14; ParisGoogle Scholar
  30. 30.
    Johnson & Johnson. Simponi™ (Golimumab) receives FDA approval as first once-monthly anti-TNF for treatment of rheumatoid arthritis, psoriatic arthritis: first subcutaneous anti-TNF to launch with three rheumatic indications simultaneously and with novel SmartJectTM autoinjector [online]. Available from URL: http://www.jnj.com/connect/news/all/20090424_150000 [Accessed 2009 Apr 28]
  31. 31.
    Schering-Plough. Health Canada approves Simponi(TM) (golimumab) for treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis [online]. Available from URL: http://www.schering-plough.com/news/news_article.aspx?requid=1275742 [Accessed 2009 Apr 24]

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North ShoreNew Zealand
  2. 2.Wolters Kluwer HealthPhiladelphiaUSA

Personalised recommendations